Literature DB >> 34201458

Effect of Preoperative Immunonutrition on Postoperative Major Morbidity after Cytoreductive Surgery and HIPEC in Patients with Peritoneal Metastasis.

Alba Fernández-Candela1, Alicia Calero1, Luís Sánchez-Guillén1, Javier Escrig-Sos2, José A Barreras1, Francisco López-Rodríguez-Arias1, Laura Armañanzas1,3, Ana Murcia4, Antonio Arroyo1,3, Francisco Javier Lacueva1,3.   

Abstract

The effect of preoperative immunonutrition intake on postoperative major complications in patients following cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC) was assessed. The accuracy of C-Reactive Protein (CRP) for detecting postoperative complications was also analyzed. Patients treated within a peritoneal carcinomatosis program in which a complete or optimal cytoreduction was achieved were retrospectively analyzed. They were divided into two groups based on whether preoperative immunonutrition (IMN) or not (non-IMN) were administered. Clinical and surgical variables and postoperative complications were gathered. Predictive values of major morbidity of CRP during the first 3 postoperative days (POD) were also evaluated. A total of 107 patients were included, 48 belonging to the IMN group and 59 to the non-IMN group. In multivariate analysis immunonutrition (OR 0.247; 95%CI 0.071-0.859; p = 0.028), and the number of visceral resections (OR 1.947; 95%CI 1.086-3.488; p = 0.025) emerged as independent factors associated with postoperative major morbidity. CRP values above 103 mg/L yielded a negative predictive value of 84%. Preoperative intake of immunonutrition was associated with a decrease of postoperative major morbidity and might be recommended to patients with peritoneal carcinomatosis following CRS. Measuring CRP levels during the 3 first postoperative days is useful to rule out major morbidity.

Entities:  

Keywords:  C-reactive protein; cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC); immunonutrition; peritoneal carcinomatosis; peritoneal metastasis; postoperative complications

Year:  2021        PMID: 34201458     DOI: 10.3390/nu13072147

Source DB:  PubMed          Journal:  Nutrients        ISSN: 2072-6643            Impact factor:   5.717


  30 in total

Review 1.  Complications of Cytoreductive Surgery and HIPEC in the Treatment of Peritoneal Metastases.

Authors:  Sanket S Mehta; Maxilliano Gelli; Deepesh Agarwal; Diane Goéré
Journal:  Indian J Surg Oncol       Date:  2016-02-10

Review 2.  Role of hyperthermic intraoperative peritoneal chemotherapy in the management of peritoneal metastases.

Authors:  D Elias; D Goéré; F Dumont; C Honoré; P Dartigues; A Stoclin; D Malka; V Boige; M Ducreux
Journal:  Eur J Cancer       Date:  2013-10-21       Impact factor: 9.162

3.  8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.

Authors:  Vic J Verwaal; Sjoerd Bruin; Henk Boot; Gooike van Slooten; Harm van Tinteren
Journal:  Ann Surg Oncol       Date:  2008-06-03       Impact factor: 5.344

Review 4.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a review of factors contributing to morbidity and mortality.

Authors:  Andrew D Newton; Edmund K Bartlett; Giorgos C Karakousis
Journal:  J Gastrointest Oncol       Date:  2016-02

5.  Predictors of Severe Morbidity After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Patients With Colorectal Peritoneal Carcinomatosis.

Authors:  Geert A Simkens; Thijs R van Oudheusden; Misha D Luyer; Simon W Nienhuijs; Grard A Nieuwenhuijzen; Harm J Rutten; Ignace H de Hingh
Journal:  Ann Surg Oncol       Date:  2015-10-06       Impact factor: 5.344

Review 6.  It's time to warm up to hyperthermic intraperitoneal chemotherapy for patients with ovarian cancer.

Authors:  Oliver Zivanovic; Dennis S Chi; Olga Filippova; Leslie M Randall; Robert E Bristow; Roisin E O'Cearbhaill
Journal:  Gynecol Oncol       Date:  2018-09-22       Impact factor: 5.482

7.  Diagnostic Accuracy of Procalcitonin and C-reactive Protein for the Early Diagnosis of Intra-abdominal Infection After Elective Colorectal Surgery: A Meta-analysis.

Authors:  François Cousin; Pablo Ortega-Deballon; Abderrahmane Bourredjem; Alexandre Doussot; Valentina Giaccaglia; Isabelle Fournel
Journal:  Ann Surg       Date:  2016-08       Impact factor: 12.969

8.  Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial.

Authors:  François Quénet; Dominique Elias; Lise Roca; Diane Goéré; Laurent Ghouti; Marc Pocard; Olivier Facy; Catherine Arvieux; Gérard Lorimier; Denis Pezet; Frédéric Marchal; Valeria Loi; Pierre Meeus; Beata Juzyna; Hélène de Forges; Jacques Paineau; Olivier Glehen
Journal:  Lancet Oncol       Date:  2021-01-18       Impact factor: 41.316

9.  Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.

Authors:  Willemien J van Driel; Simone N Koole; Karolina Sikorska; Jules H Schagen van Leeuwen; Henk W R Schreuder; Ralph H M Hermans; Ignace H J T de Hingh; Jacobus van der Velden; Henriëtte J Arts; Leon F A G Massuger; Arend G J Aalbers; Victor J Verwaal; Jacobien M Kieffer; Koen K Van de Vijver; Harm van Tinteren; Neil K Aaronson; Gabe S Sonke
Journal:  N Engl J Med       Date:  2018-01-18       Impact factor: 91.245

10.  Morbidity and Mortality Rates Following Cytoreductive Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy Compared With Other High-Risk Surgical Oncology Procedures.

Authors:  Jason M Foster; Richard Sleightholm; Asish Patel; Valerie Shostrom; Bradley Hall; Beth Neilsen; David Bartlett; Lynette Smith
Journal:  JAMA Netw Open       Date:  2019-01-04
View more
  2 in total

1.  Randomized Controlled Trial Investigating Perioperative Immunonutrition for Patients Undergoing Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).

Authors:  Grace Hwei Ching Tan; Claramae Shulyn Chia; Jolene Si Min Wong; Whee Sze Ong; Hong-Yuan Zhu; Chin-Ann Johnny Ong; Melissa Ching Ching Teo
Journal:  Ann Surg Oncol       Date:  2022-09-30       Impact factor: 4.339

Review 2.  Prehabilitation to Improve Outcomes of Patients with Gynaecological Cancer: A New Window of Opportunity?

Authors:  Joëlle Dhanis; Nathaniel Keidan; Dominic Blake; Stuart Rundle; Dieuwke Strijker; Maaike van Ham; Johanna M A Pijnenborg; Anke Smits
Journal:  Cancers (Basel)       Date:  2022-07-15       Impact factor: 6.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.